Siemens receives FDA clearance for new x-ray system

Siemens Healthcare announced this week that it has received FDA clearance for its Multitom Rax x-ray system, which allows numerous imaging exams to be performed in one room, with the same equipment.

The technology behind the Multitom Rax system—”Rax” is short for robotic advanced x-ray—is the first of its kind, said Martin Silverman, Siemens Healthcare North America’s vice president of x-ray products.

“With the Multitom Rax, Siemens is proud to introduce the world’s first Twin Robotic X-ray system,” Silverman said in a statement. “This universal X-ray system delivers unprecedented versatility for health care facilities. Now, clinicians can perform a multitude of imaging exams in one room without moving the patient. With the Multitom Rax, we’re opening a new chapter in X-ray technology.”

The system consists of an adjustable patient table and two ceiling-mounted robotic arms to carry out the exams. Its custom design allows providers to capture 3D natural weight-bearing images for the first time; patients can be seated, standing up, or on their back.

Siemens noted in its statement that the system boasts numerous built-in features, including Comprehensive CARE (Combined Applications to Reduce Exposure), which help reduce patient radiation dose.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The new F-18 flurpiridaz radiotracer is expected to help drive cardiac PET growth, but it requires waiting between rest and stress scans. Software from MultiFunctional Imaging can help care teams combat that problem.

News of an incident is a stark reminder that healthcare workers and patients aren’t the only ones who need to be aware around MRI suites.

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.